FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Stopped early · Phase 1

Conditions studied: Advanced Synovial Sarcoma

In brief

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors.

Key facts

Study ID

NCT04965753

Run by

Foghorn Therapeutics Inc.

People needed

55

Starts

2021-08-17

Expected to finish

2023-12-04

Last updated by the study team

2025-03-04

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be ≥ 18 or ≥ 16 years of age with a minimum body weight of 50 kg.
• Subject must have a diagnosis of SS or a SMARCB1-loss tumor:
• SS:
• Evidence of the SS18-SSX rearrangement and/or a confirmed pathologic diagnosis of SS must be available.
• May be treatment naïve or previously treated (see definition below)
• SMARCB1-loss tumor:
• A solid tumor primarily characterized by SMARCB1 loss (eg, malignant rhabdoid tumors, epithelioid sarcoma, poorly differentiated chordoma) Documentation of biallelic SMARCB1 alterations and/or corresponding protein loss, and/or a confirmed pathologic diagnosis of a solid tumor primarily characterized by SMARCB1 loss, must be available.
• Other solid tumors with SMARCB1 loss. Documentation of biallelic SMARCB1 alterations and/or corresponding protein loss must be available.
• Note: Inclusion criterion 15 provides timing requirements for prior therapy.
• Subject must have measurable disease by RECIST v1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥ 10 mm with calipers and/or CT scan. Measurable lesions cannot have undergone any local treatment or radiation unless the lesion has progressed post treatment nor can any local treatment or radiation involving measurable lesions be anticipated. Exceptions to the requirements for measurable disease may be made in discussion with the sponsor.
• Subject or his/her parent or legal guardian (when applicable) must be able to understand and be willing to sign an informed consent and, when applicable, subject must sign assent form.
• Subject must be willing and able to comply with scheduled study visits and treatment plans.
• Subject must be willing to undergo all study procedures (biopsies at baseline, at least 1 on-treatment and at EOT [unless contraindicated due to medical risk; other exceptions to this are at the discretion of the Sponsor]), laboratory testing, and imaging approximately every 8 (or 12) weeks independent of dose delays, interruptions, and/or reductions.
• Subject must have an ECOG PS of ≤ 2.
• Arm 2 (Dose Expansion Phase): Subject must have an ECOG PS of ≤ 3
• Subject must have a life expectancy of ≥ 3 months.
• Arm 2 (Dose Expansion Phase): Subject must have a life expectancy of ≥ 2 months
• Subject must have adequate venous access for IV drug administration and blood collection.
• Subject must have adequate cardiac function as evidenced by:
• LVEF of ≥ 40% by ECHO. Other methods of evaluating LVEF may be performed according to institutional practice.
• Corrected QT interval (QTc) using Fridericia's formula (QTcF) < 470 msec
• Subject must have adequate hepatic function as evidenced by:
• Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (≤ 3.0 × ULN for subjects with Gilbert's syndrome)
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3.0 × ULN (≤ 5.0 × ULN if liver metastases are present)
• Alkaline phosphatase (ALP) ≤ 3.0 × ULN (≤ 5.0 × ULN if liver metastases are present and/or known bone disease is present)

You may not qualify if…

• Subject (or parent or legal guardian, when applicable) is unable to provide informed consent (or assent, when applicable) and/or to follow protocol requirements.
• Subject has other malignancy which may interfere with the diagnosis and/or treatment of SS/SMARCB1-loss tumors and/or interpretation of outcome results.
• Subject has an active severe infection requiring systemic therapy. Subject is permitted to enroll once any required antibiotic and/or antifungal therapy has been completed and/or infection is determined to be controlled.
• Subject has active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections; subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Subject has known positive human immunodeficiency virus (HIV) antibody results or acquired immunodeficiency syndrome (AIDS)-related illness; subjects with CD4+ T-cell counts ≥ 350 cells/µL will be permitted, as will subjects who have not had an AIDS-related illness within the past 12 months.
• Subject has an uncontrolled concurrent medical disease and/or psychiatric illness/social situation that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol.
• Subject is requiring clinically significant or increasing doses of systemic steroid therapy for acute illness (stable doses for controlled chronic disease or symptoms are permitted) or any other systemic immunosuppressive medication. Stable doses of systemic immunosuppressive medications may be allowed with Sponsor approval. Local or targeted steroid and immunosuppressive therapies (eg, inhaled or topical steroids) are acceptable. See Exclusion criterion 7 for details on steroids in the setting of central nervous system (CNS) disease.
• Subjects with known CNS metastases are only permitted under the following conditions: Brain metastases must have been stable for approximately 2 months since completion of most recent CNS-directed intervention. Subject may be receiving corticosteroids so long as the dose is stable or decreasing at the time of study entry. Anti-epileptic therapy is allowed so long as medications are not otherwise excluded and seizures have been controlled for approximately 4 weeks since the last anti-epileptic medication adjustment. Subjects with active brain metastases and/or leptomeningeal disease are excluded. Exceptions to this may be made on a case-by-case basis with approval of Sponsor.
• Dose Escalation Phase: Subjects with known CNS metastases that meet the above conditions are permitted to enroll in dose escalation.
• Arm 1 and Arm 3 (Dose Expansion Phase): Subjects with known or suspected CNS metastases are excluded from Arm 1 and Arm 3.
• Arm 2 (Dose Expansion Phase): Subjects with CNS metastases that meet the above conditions are permitted to enroll in Arm 2.
• Subject has known hypersensitivities to components of FHD-609.
• Subject has prior exposure to a BRD9 degrader.
• Subject is participating in any other clinical trials. Exceptions include participation in any observational or nontherapeutic clinical trials.

Where it is running

• City of Hope — Duarte, California, United States
• University of Miami Health System — Miami, Florida, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
• Centre Leon Berard — Lyon, France
• Institut Gustave Roussy — Villejuif, France
• Istituto Nazionale dei Tumori — Milan, Italy
• Hospital Universitari Vall d'Hebron — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.